Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
721-740 of 936 trials

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

BI 3031185: Tolerance Study in Healthy Men

We are testing how well different doses of a new medication are tolerated by healthy men. This study aims to gather important safety information for future use.

Healthy VolunteersSafety phase (I)

EPI/HIS Trial: Exploring New Treatment Options

We are investigating a new approach for managing health conditions. This trial aims to understand its effects on patient outcomes.

Healthy Participants>2 yearsSafety phase (I)Internal Medicine

Cancer Treatment: NEXTGEN-TIL-ACT Study

We are assessing a new therapy using tumor-infiltrating lymphocytes for cancer patients. The goal is to evaluate how safe and tolerable this treatment is.

Malignant Solid Tumor>2 yearsSafety phase (I)Oncology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicinePediatrics

Advanced Melanoma: New Treatment Combination

We are studying a new treatment approach for patients with advanced melanoma, combining immune therapies to see if it improves outcomes and reduces side effects. This trial aims to understand how well these treatments work together.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Multiple Myeloma: ABBV-453 Treatment Study

We are studying the safety and effects of ABBV-453, alone or with other treatments, for adults with multiple myeloma. This research aims to understand how well it works and how it is tolerated by patients.

Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: GSK5733584 with Anti-Cancer Therapies

We are studying a new drug, GSK5733584, combined with other cancer treatments for patients with advanced solid tumors. The trial aims to evaluate its safety and how well it may work in this setting.

Gynecological TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Antibiotics in Bile Fluid: A Study for Patients with Biliary Drainage

We are investigating how antibiotics are processed in the bile of patients with external biliary drainage. This research may help improve treatment strategies for these patients.

Cholangitis1-2 yearsSafety phase (I)GastroenterologyHepatology

Refractory Solid Tumors: Propranolol and Vinorelbine Study

We are testing a combination of Propranolol and Vinorelbine in children and teenagers with hard-to-treat solid tumors. The study aims to find the safest dose and evaluate how well this treatment works over time.

Malignant GliomaMalignant Solid TumorDesmoid Tumor>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

MDS and CMML: PXS-5505 with 5-Azacitidine

We are studying a new treatment combining PXS-5505 and 5-Azacitidine for patients with MDS and CMML. The goal is to evaluate its safety and effectiveness compared to standard therapies.

Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

SOD1 ALS: AMT-162 Gene Therapy

We are testing a new gene therapy for adults with SOD1 amyotrophic lateral sclerosis to see if it is safe and well-tolerated. We’re also exploring its potential effects on the disease.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Anti-Infection Drugs: Healthy vs. Severely Burned Patients

We are investigating how the body processes anti-infection drugs in healthy people compared to those with severe burns in the ICU. This study aims to improve treatment strategies for burn patients.

Burns>2 yearsSafety phase (I)DermatologyInfectious DiseasesInternal Medicine

BOTOX® for Preventing Pancreatic Fistula After Surgery

We are studying whether BOTOX® injections before surgery can help prevent complications in patients undergoing distal pancreatectomy. This trial will assess the safety and effectiveness of this approach.

Postoperative Pancreatic Fistulas≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

T-Guard for Early Diffuse Cutaneous Systemic Sclerosis

We are studying the safety and effectiveness of T-Guard in patients with early diffuse cutaneous systemic sclerosis. This trial will help us understand how well the treatment works and how it is processed in the body.

Diffuse Systemic Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyInternal MedicineRheumatology

Hydrocortisone Absorption: Oral vs. Oral Mucosa

We are comparing how well hydrocortisone is absorbed from dissolvable films in healthy volunteers and adults with adrenal insufficiency. This study aims to find the most effective way to deliver this important medication.

Adrenal Insufficiency1-2 yearsSafety phase (I)Endocrinology

EGFR-Mutant Non-Small Cell Lung Cancer: BG-60366 Study

We are investigating a new treatment for patients with EGFR-mutant non-small cell lung cancer. The study will help us understand its safety and how well it works against the cancer.

EGFR-Mutant Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Alcohol Use Disorder: Psilocybin Treatment

We are studying if a single dose of psilocybin can help reduce heavy drinking in people with alcohol use disorder. This trial compares the effects of psilocybin to a placebo over 12 weeks.

Alcohol Use Disorder>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Efgartigimod and Emasiprubart: Healthy Adult Study

We are examining how the drug efgartigimod affects emasiprubart in healthy adults. This research aims to gather information on their interaction for future treatments.

Healthy Participants1-2 yearsSafety phase (I)